Huang Bin, Kochanek Stefan
Division of Gene Therapy, University of Ulm, D-89081 Ulm, Germany.
Hum Gene Ther. 2005 May;16(5):618-26. doi: 10.1089/hum.2005.16.618.
Huntington's disease (HD) is an inherited autosomal dominant, neurodegenerative disease that is caused by a gain of function mutation characterized by the expansion of a CAG trinucleotide repeat in exon 1 of the huntingtin (htt) gene. Since hairpin small interference RNA (shRNA) technology allows inhibition of specific gene expression in vitro and in vivo, vector-mediated expression of an shRNA directed to htt mRNA could form the basis of a new treatment modality for HD. By initial plasmid transfection of 293 cells, we identified one exon 1-targeted shRNA, which efficiently inhibited expression of an htt exon 1-GFP fusion protein and the endogenous htt gene. A replication-deficient adenovirus (Ad) vector Adie-1-1 was constructed to express this shRNA from the U6 promoter. In A549 cells expressing exon 1 of htt with an expanded CAG allele, Adie- 1-1 efficiently prevented htt exon 1 expression and htt aggregate formation. In addition, in different neuronal and nonneuronal cell lines, Adie-1-1 efficiently inhibited the expression of endogenous htt. Together, this data indicates the delineation of an shRNA strategy that may become the basis for treatment of HD.
亨廷顿舞蹈症(HD)是一种常染色体显性遗传的神经退行性疾病,由功能获得性突变引起,其特征是亨廷顿蛋白(htt)基因第1外显子中的CAG三核苷酸重复序列发生扩增。由于发夹状小干扰RNA(shRNA)技术能够在体外和体内抑制特定基因的表达,因此,载体介导的针对htt mRNA的shRNA表达可能成为HD新治疗方式的基础。通过对293细胞进行初始质粒转染,我们鉴定出一种靶向第1外显子的shRNA,它能有效抑制htt第1外显子-GFP融合蛋白以及内源性htt基因的表达。构建了一种复制缺陷型腺病毒(Ad)载体Adie-1-1,用于从U6启动子表达这种shRNA。在表达带有扩增CAG等位基因的htt第1外显子的A549细胞中,Adie-1-1有效阻止了htt第1外显子的表达和htt聚集体的形成。此外,在不同的神经元和非神经元细胞系中,Adie-1-1有效抑制了内源性htt的表达。总之,这些数据表明了一种shRNA策略,它可能成为HD治疗的基础。